NASDAQ:IMVT

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant closed a $550 million stock offering on December 12, 2025, selling 26.2 million shares at $21 each. Roivant Sciences bought 16.7 million shares, investing about $350 million and increasing its stake. IMVT shares ended the week at $26.42, up 6.6% after heavy trading. The company plans to use proceeds to fund clinical trials and general operations.

14 December 2025

Biotechnology·NASDAQ:IMVT

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant shares rose 9% to $25.75 Thursday after the company announced a $550 million common stock offering to fund development and possible launch of its lead drug, IMVT‑1402, for Graves’ disease. The offering priced at $21 per share, an 11% discount, and is expected to close December 12. Roivant Sciences will participate. Immunovant’s market value reached about $4 billion.

11 December 2025

Biotechnology·Healthcare News·NASDAQ:IMVT·Pharmaceuticals·Stock Market

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).